Reven Holdings Announces the Launch of Its Translational Oncology Program: Targeting Tumor Microenvironment to Improve Treatment Outcomes in Cancer

Reven has launched its translational oncology program as a new drug discovery and development initiative that is aimed at changing the therapeutic landscape for difficult-to-treat forms of cancer. The overarching goal of this program is to treat cancer patients more effectively by altering the immediate surroundings of their tumor tissue, also known as the tumor microenvironment (TME). … Read More The post Reven Holdings Announces the Launch of Its Translational Oncology Program: Targeting Tumor Microenvironment to Improve Treatment Outcomes in Cancer appeared first on Reven Pharmaceuticals .